US biosimilars information guides and support for cancer biosimilars

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

US biosimilars information guides and support for cancer biosimilars

Biosimilars/General | Posted 02/07/2021 0 Post your comment

Pharmaceutical giant, Pfizer, and the Cancer Support Community, in the US, have published guides to biosimilars. In addition, Pfizer is collaborating with The National Comprehensive Cancer Network® (NCCN®) to fund projects to support innovation related to appropriate biosimilar adoption in oncology.

Furthermore, Pfizer has published information on biosimilars for patients. This includes background information on what biosimilars are and the standards for biosimilarity. It also includes a video which emphasizes that biosimilars provide patients with more safe, effective and often lower-cost treatment options.

The Cancer Support Community has published a quick guide to biosimilars in the US. This guide is available online [1] and gives a background to biosimilars and what they are, how they are approved and how drugs are named. In addition, it gives details on the biosimilars available to treat cancers and how they are prescribed.

In addition, on 15 March 2021, a collaboration between Pfizer and NCCN’s Oncology Research Program (ORP), in the US, announced the funding of 10 projects to support innovative approaches to improve the processes related to appropriate biosimilar adoption in oncology.

The NCCN is a not-for-profit alliance of leading cancer centres in the US, devoted to patient care, research and education. Together with Pfizer, they will be supporting projects run by institutions such as The Cancer Support Community, the Universities of Texas and Illinois and the American Society of Clinical Oncology (ASCO). These will investigate aspects of processes related to biosimilar adoption such as oncology patient and caregiver perceptions, challenges to biosimilar adoption in community oncology due to diverse payer preferences for different biosimilars and identifying best practices in biosimilars implementation. In addition, there will be the development of a human-centred information packet to increase trastuzumab biosimilars uptake, and a clinical decision support tool for biosimilar use in oncology.

Related articles
Biosimilar approvals and launches in the US

Biosimilar toolkit for cancer patients

Clinical review of biosimilar approved in oncology

Barriers to biosimilars access in the US

LATIN AMERICAN FORUM The brand-new section the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. View this week’s headline article: La Epoetina biosimilar en Estados Unidos – obstáculos y recomendaciones Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative. LATIN AMERICAN FORUM Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español. Vea el artículo principal de esta semana: La Epoetina biosimilar en Estados Unidos – obstáculos y recomendaciones Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa.

Reference
1. Cancer Support Community. What is a biosimilar [homepage on the Internet]. [cited 2021 Jul 2]. Available from: https://www.cancersupportcommunity.org/what-biosimilar

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Pfizer